ArticleEClinicalMedicine2026
Recurrence after healing in pyoderma gangrenosum: a prospective registry-based cohort study.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pyoderma gangrenosum is a rare neutrophilic dermatosis with potential for relapse after healing, yet recurrence in real-world settings remains unknown. We aimed to evaluate recurrence patterns to inform clinical practice and future research. Methods: Data were abstracted from a uniquely, prospectively maintained pyoderma gangrenosum registry. A cohort of patients with pyoderma gangrenosum seen between December 1st, 2019 and March 1st, 2026 who healed within this timeframe was identified. Two subgroups were then created: those who remained healed, and those who had a recurrence. Descriptive statistics summarised recurrence characteristics; Kaplan-Meier methods estimated a cumulative incidence of recurrence, and Cox proportional hazards modelling identified predictors of recurrence. Findings: Of 116 patients with healed pyoderma gangrenosum, 41 (35%) experienced a recurrence, generating a recurrence proportion of 35·3% (95% CI 26·7-44·8). Nominal associations with recurrence on univariable analysis included history of diabetes mellitus (hazard ratio 2·1, 95% CI 1·1-4·0, p = 0·024) and ever-smoking (1·8, 1·0-3·4, p = 0·057). Baseline characteristics differing between recurrence and non-recurrence groups included age (p = 0·033), history of diabetes (p = 0·0060), and ulcer age at presentation (p = 0·046). Cumulative recurrence risk was calculated as 27% (95% CI 18·1-35·0) at 1 year and 41·3% (95% CI 30·4-50·5) at 5 years. Interpretation: Pyoderma gangrenosum recurred in approximately a third of patients. A history of diabetes showed a borderline association with recurrence, while the univariable signal for smoking was attenuated after adjustment. Recurrence risk remains elevated five years after initial healing, and peristomal pyoderma gangrenosum is associated with higher recurrence rates, suggesting that maintenance therapy may be necessary for certain patient populations after achieving ulcer closure. Our data highlight the need for prospective evaluation of maintenance approaches. Future work will focus on individual recurrence predictors. Funding: This is an unfunded study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.